BR112023016273A2 - Inibidores de vmat2 e métodos de uso - Google Patents
Inibidores de vmat2 e métodos de usoInfo
- Publication number
- BR112023016273A2 BR112023016273A2 BR112023016273A BR112023016273A BR112023016273A2 BR 112023016273 A2 BR112023016273 A2 BR 112023016273A2 BR 112023016273 A BR112023016273 A BR 112023016273A BR 112023016273 A BR112023016273 A BR 112023016273A BR 112023016273 A2 BR112023016273 A2 BR 112023016273A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- vmat2 inhibitors
- vmat2
- inhibitors
- compositions
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
inibidores de vmat2 e métodos de uso. a presente invenção refere-se de um modo geral a compostos inibidores de vmat2 de fórmula (i), composições e métodos relacionados aos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164135P | 2021-03-22 | 2021-03-22 | |
| PCT/US2022/021080 WO2022203984A1 (en) | 2021-03-22 | 2022-03-21 | Vmat2 inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016273A2 true BR112023016273A2 (pt) | 2023-10-03 |
Family
ID=81325053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016273A BR112023016273A2 (pt) | 2021-03-22 | 2022-03-21 | Inibidores de vmat2 e métodos de uso |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11718618B2 (pt) |
| EP (1) | EP4168409A1 (pt) |
| JP (1) | JP2024511053A (pt) |
| KR (1) | KR20230160308A (pt) |
| CN (1) | CN117062815A (pt) |
| AR (1) | AR125188A1 (pt) |
| AU (1) | AU2022241988A1 (pt) |
| BR (1) | BR112023016273A2 (pt) |
| CA (1) | CA3207452A1 (pt) |
| CL (1) | CL2023002785A1 (pt) |
| CO (1) | CO2023012322A2 (pt) |
| CR (1) | CR20230448A (pt) |
| DO (1) | DOP2023000197A (pt) |
| EC (1) | ECSP23070370A (pt) |
| IL (1) | IL305054A (pt) |
| MX (1) | MX2023010566A (pt) |
| PE (1) | PE20240822A1 (pt) |
| TW (1) | TW202304901A (pt) |
| WO (1) | WO2022203984A1 (pt) |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3209005A (en) | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| EP2604290A3 (en) | 2006-05-02 | 2013-07-10 | The Trustees of The University of Pennsylvania | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| EA018378B1 (ru) | 2006-11-08 | 2013-07-30 | Ньюрокрайн Байосайенсиз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ |
| US8008500B2 (en) | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US7897769B2 (en) | 2007-10-25 | 2011-03-01 | General Electric Company | Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes |
| US7902364B2 (en) | 2007-11-29 | 2011-03-08 | General Electric Company | Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| US8053578B2 (en) * | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| US7910738B2 (en) | 2007-11-29 | 2011-03-22 | General Electric Company | Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| US7919622B2 (en) | 2007-12-07 | 2011-04-05 | Kande Kankanamalage Dayarathna Amarasinghe | Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes |
| US8013161B1 (en) | 2007-12-07 | 2011-09-06 | General Electric Company | Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| US20120003330A1 (en) | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CN109125745B (zh) | 2012-04-10 | 2022-07-26 | 蓝瑟斯医学影像公司 | 放射性药物合成方法 |
| CN111728971A (zh) | 2012-09-18 | 2020-10-02 | 奥斯拜客斯制药有限公司 | D6-四苯喹嗪固体口服剂型、化合物、及其药物组合物、制备及治疗方法 |
| CA2896202A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
| EA201500801A1 (ru) | 2013-01-31 | 2016-01-29 | Ауспекс Фармацетикалс, Инк. | Бензохинолоновые ингибиторы vmat2 |
| WO2014144064A2 (en) | 2013-03-15 | 2014-09-18 | University Of Kentucky Research Foundation | 1,4-disubstituted piperidines, 1,4-disubstituted piperazines, 1,4-disubstituted diazepanes, and 1,3-disubstituted pyrrolidine compounds |
| GB201313291D0 (en) | 2013-07-25 | 2013-09-11 | Ge Healthcare Ltd | Imaging neurological disease |
| WO2015077521A1 (en) | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| KR20160111999A (ko) | 2014-01-27 | 2016-09-27 | 오스펙스 파마슈티칼스, 인코포레이티드 | 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제 |
| NZ733899A (en) | 2015-02-06 | 2024-01-26 | Neurocrine Biosciences Inc | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| JP6869988B2 (ja) | 2015-12-23 | 2021-05-12 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法 |
| US10668030B2 (en) | 2016-04-21 | 2020-06-02 | University Of Kentucky Research Foundation | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| TW201906818A (zh) | 2017-05-31 | 2019-02-16 | 美商５１１製藥公司 | 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用 |
| CN111343985A (zh) | 2017-11-08 | 2020-06-26 | 逸达生物科技股份有限公司 | 二氢丁苯那嗪的酯 |
| TW202033521A (zh) | 2018-10-24 | 2020-09-16 | 美商紐羅克里生物科學有限公司 | 製備囊泡單胺轉運蛋白2(vmat2)抑制劑之方法 |
| US20220340562A1 (en) | 2019-08-12 | 2022-10-27 | Shandong Luye Pharmaceutical Co., Ltd. | Vmat2 inhibitor and preparation method therefor and application thereof |
| US20210087191A1 (en) | 2020-12-04 | 2021-03-25 | Dispersol Technologies, Llc | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| IL310907A (en) | 2021-08-20 | 2024-04-01 | Neurocrine Biosciences Inc | Screening methods for VMAT2 inhibitors |
-
2022
- 2022-03-21 CA CA3207452A patent/CA3207452A1/en active Pending
- 2022-03-21 EP EP22715479.6A patent/EP4168409A1/en active Pending
- 2022-03-21 CN CN202280023462.8A patent/CN117062815A/zh active Pending
- 2022-03-21 KR KR1020237035676A patent/KR20230160308A/ko unknown
- 2022-03-21 MX MX2023010566A patent/MX2023010566A/es unknown
- 2022-03-21 BR BR112023016273A patent/BR112023016273A2/pt unknown
- 2022-03-21 AU AU2022241988A patent/AU2022241988A1/en active Pending
- 2022-03-21 WO PCT/US2022/021080 patent/WO2022203984A1/en active Application Filing
- 2022-03-21 IL IL305054A patent/IL305054A/en unknown
- 2022-03-21 JP JP2023557361A patent/JP2024511053A/ja active Pending
- 2022-03-21 TW TW111110403A patent/TW202304901A/zh unknown
- 2022-03-21 PE PE2023002681A patent/PE20240822A1/es unknown
- 2022-03-21 AR ARP220100663A patent/AR125188A1/es unknown
- 2022-03-21 CR CR20230448A patent/CR20230448A/es unknown
-
2023
- 2023-01-12 US US18/096,073 patent/US11718618B2/en active Active
- 2023-06-09 US US18/207,807 patent/US20240010647A1/en active Pending
- 2023-09-18 DO DO2023000197A patent/DOP2023000197A/es unknown
- 2023-09-18 CO CONC2023/0012322A patent/CO2023012322A2/es unknown
- 2023-09-18 EC ECSENADI202370370A patent/ECSP23070370A/es unknown
- 2023-09-20 CL CL2023002785A patent/CL2023002785A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202304901A (zh) | 2023-02-01 |
| MX2023010566A (es) | 2023-09-21 |
| CO2023012322A2 (es) | 2023-10-09 |
| PE20240822A1 (es) | 2024-04-18 |
| EP4168409A1 (en) | 2023-04-26 |
| DOP2023000197A (es) | 2023-11-15 |
| US11718618B2 (en) | 2023-08-08 |
| CA3207452A1 (en) | 2022-09-29 |
| US20240010647A1 (en) | 2024-01-11 |
| US20230159528A1 (en) | 2023-05-25 |
| KR20230160308A (ko) | 2023-11-23 |
| IL305054A (en) | 2023-10-01 |
| ECSP23070370A (es) | 2023-10-31 |
| AU2022241988A1 (en) | 2023-10-12 |
| CN117062815A (zh) | 2023-11-14 |
| AR125188A1 (es) | 2023-06-21 |
| CR20230448A (es) | 2023-10-27 |
| JP2024511053A (ja) | 2024-03-12 |
| CL2023002785A1 (es) | 2024-02-02 |
| WO2022203984A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| MX2022007527A (es) | Inhibidores de proteinas kras mutantes. | |
| BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
| PH12021500013A1 (en) | New heterocyclic compounds as monoacylgylcerol lipase inhibitors | |
| PH12020550034A1 (en) | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor | |
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| UY39526A (es) | Inhibidores de kras g12d | |
| MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
| EA202092263A1 (ru) | Аминопиридиновые производные в качестве ингибиторов ctps1 | |
| CO2019002692A2 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. | |
| BR112022003982A2 (pt) | Compostos heterocíclicos | |
| UY37764A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
| BR112023023527A2 (pt) | Inibidores de nlrp3 | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| MD3680243T2 (ro) | Compus pentaciclic | |
| MX2019013979A (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| BR112022018828A2 (pt) | Derivados de benzodiazepina como gaba a gamma1 pams | |
| CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
| CL2020002216A1 (es) | Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificación | |
| BR112021023635A2 (pt) | Novos compostos para inibição de janus quinase 1 | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| MX2021004386A (es) | Compuestos novedosos. | |
| WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
| CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 |